Latisse (Bimatoprost)

Description

What Is Latisse

Latisse is a prescription topical solution used to treat hypotrichosis of the eyelashes — a condition where lashes are thinner, shorter, or sparser than desired. Manufactured by Allergan, its active ingredient is bimatoprost, a prostaglandin analogue applied nightly to the base of the upper lash line. Latisse is not a cosmetic conditioner; it works at the level of the hair follicle to produce measurably longer, thicker, and darker eyelashes.

How Latisse Works

Bimatoprost interacts with prostamide-sensitive receptors in the hair follicle to extend the anagen phase — the active growth stage of the hair cycle. A longer anagen phase means more lashes are growing at once, and each one grows for longer before shedding. This produces the three changes patients notice most: increased length, increased thickness, and darker pigmentation.

Bimatoprost was originally formulated at the same concentration for glaucoma treatment, where it lowers intraocular pressure. Eyelash growth was identified as a side effect in glaucoma patients before Allergan developed a dedicated eyelash formulation and pursued a separate approval specifically for hypotrichosis. Histological studies of treated follicles show a measurable increase in the proportion of hairs in the anagen phase and in overall follicle size, which is the biological basis for the length and thickness gains seen in trials.

It's worth distinguishing this mechanism from what most cosmetic lash products do. Conditioning serums and mascaras work on the surface of the existing hair shaft, reducing breakage or adding volume optically. Bimatoprost changes the growth cycle underneath the skin, which is why the effect takes months to appear and why it requires a prescription rather than sitting on an open shelf.

Clinical Evidence

• In the pivotal 16-week, randomized, vehicle-controlled trial, patients using bimatoprost 0.03% showed statistically significant increases in eyelash length, thickness, and darkness compared with the inactive vehicle group
• A majority of patients achieved at least a one-grade improvement on the Global Eyelash Assessment scale by week 16
• Visible change typically begins at 4–8 weeks, with full results at approximately 16 weeks of consistent nightly use
• Results are not permanent — eyelashes gradually return to baseline over several weeks to months after discontinuation, since the effect depends on the follicle staying in an extended growth cycle
• The most frequently reported adverse event across trials was mild conjunctival redness, occurring at a statistically higher rate than in the vehicle-control group but generally not severe enough to cause discontinuation
• Safety data from a 16-week pediatric and adolescent study, conducted in patients with hypotrichosis related to chemotherapy or alopecia areata as well as those with no associated medical condition, did not identify new safety signals beyond what's seen in adults

How to Use Latisse

1. Remove makeup and contact lenses, and ensure the face is clean and dry
2. Apply one drop to the sterile applicator provided
3. Draw the applicator along the skin at the base of the upper eyelash line only — do not apply to the lower lash line or inside the eye
4. Blot any excess solution beyond the eyelid margin
5. Use a fresh applicator for the opposite eye; never reuse an applicator or share one between eyes
6. Apply once nightly — more frequent application does not accelerate results

Contact lens wearers should remove lenses before application and may reinsert them 15 minutes afterward, since the preservative in Latisse (benzalkonium chloride) can be absorbed by soft lenses.

Side Effects

Common and generally reversible:

• Eye redness (conjunctival hyperemia)
• Itching or irritation at the application site
• Eyelid skin darkening
• Dryness

Less common, requiring medical attention:

• Sudden decrease in vision
• Signs of eye infection or trauma
• Eyelid or eyelash follicle reactions

Rare and potentially permanent:

• Increased brown pigmentation of the iris, more likely in individuals with hazel or green eyes containing mixed pigmentation. This risk is well established from bimatoprost's use in glaucoma treatment at similar concentrations and is minimized by correct eyelid-margin application rather than direct eye instillation

Warnings and Interactions

• Do not use if allergic to bimatoprost or any solution ingredient
• May temporarily blur vision; avoid driving or operating machinery until vision clears
• Patients already using a prostaglandin analogue (such as Lumigan) for intraocular pressure should consult their physician before adding Latisse, as combined use may interfere with pressure control
• Applicators are single-use and single-eye; reuse increases infection risk
• Not evaluated or approved for eyebrow application; off-label use elsewhere on the body is not supported by the same safety data

Latisse vs. Generic Bimatoprost

Generic bimatoprost ophthalmic solution contains the identical active ingredient at the identical 0.03% concentration and produces the same follicular effect on the same timeline. The difference between the branded and generic product is the manufacturer and applicator packaging, not the mechanism of action or expected results. Patients switching between the two should not expect a change in efficacy, though it's worth confirming that any generic version includes sterile, single-use applicators rather than a single reusable brush, since applicator hygiene affects both results and eye safety.

Cost is typically the deciding factor between the two. Branded Latisse carries a premium tied to the Allergan name and original applicator design, while the generic delivers the same active ingredient at a lower price point — a relevant consideration given that this is a maintenance product used indefinitely rather than a short course of treatment.